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OBJECTIVE: To review the current literature on human herpesvirus 8 with particular attention to the aspects related
to the etiopathogenesis of Kaposi’s sarcoma.
MATERIALS AND METHODS: The authors searched original research and review articles on specific aspects of
human herpesvirus 8 infection, including virology, epidemiology, transmission, diagnosis, natural history, therapy, and
Kaposi’s sarcoma etiopathogenesis. The relevant material was evaluated and reviewed.
RESULTS: Human herpesvirus 8 is a recently discovered DNA virus that is present throughout the world but with
major geographic variation. In the Western world, the virus, transmitted mainly by means of sexual contact, is strongly
associated with Kaposi’s sarcoma and body cavity-based lymphoma and more controversially with multiple myeloma and
other non-proliferative disorders. There is no specific effective treatment, but HIV protease inhibitors may play an indirect
role in the clearance of human herpesvirus 8 DNA from peripheral blood mononuclear cells of HIV-infected patients. Human
herpesvirus 8 DNA is present in saliva, but there are as yet no documented cases of nosocomial transmission to health care
workers. The prevalence of human herpesvirus 8 among health care workers is probably similar to that in the general
population.
CONCLUSION: Human herpesvirus 8 appears to be, at least in Western Europe and United States, restricted to a
population at risk of developing Kaposi’s sarcoma. Human herpesvirus 8 certainly has the means to overcome cellular
control and immune responses and thus predispose carriers to malignancy, particularly Kaposi’s sarcoma. The wide diffusion
of Human herpesvirus 8 in classic Kaposi’s sarcoma areas appears to represent an important factor in the high incidence of
the disease. However, additional co-factors are likely to play a role in the development of Kaposi’s sarcoma.
DESCRIPTORS: Human herpesvirus 8. KSHV. Kaposi´s sarcoma. AIDS. HIV.
INTRODUCTION
Kaposi’s sarcoma (KS) is the most
common oral malignancy of HIV dis-
ease. Epidemiological studies had pre-
viously suggested that KS may have
an infective etiology, and in 1994 a
virus termed Kaposi’s sarcoma-associ-
ated herpes virus (KSHV) or human
herpes virus-8 (HHV-8) was confirmed
to be the cause. Since the first descrip-
tion of HHV-81, more of its virology,
pathogenic mechanisms, and clinical
consequences have been elucidated.
There is strong evidence that HHV-8
not only is the causative agent of KS2
but also of primary effusion lym-
phoma (PEL) (also termed body cav-
ity-based lymphomas (BCBL)3 and
multicentric Castleman disease
(MCD)4. Human herpesvirus 8 has also
been tenuously etiologically linked
with multiple myeloma5 and non-
neoplastic disorders such as sarcoido-
sis6.
EPIDEMIOLOGY OF HHV-8 -
ASPECTS OF TRANSMISSION
Human herpesvirus 8 is principally
acquired sexually. Anal intercourse
may be particularly associated with
transmission7. In a large study of US
	
REV. HOSP. CLÍN. FAC. MED. S. PAULO 57(4):175-186, 2002 JULY-AUGUST
males, sex with other men was associ-
ated with a greater risk activity for
HHV-8 acquisition than was a history
of blood or blood products receipt or
injecting needle usage8. Likewise, in
a cohort of Danish homosexual men,
HHV-8 seropositivity correlated posi-
tively with the frequency of receptive
anal intercourse9. Females infected
with HIV by their bisexual male part-
ners were found to be at greater risk of
developing KS than those who became
HIV-infected as a consequence of vagi-
nal intercourse with male hemo-
philiacs, transfusion recipients, or in-
jecting drug users7,10.
HHV-8 is present in prostate tissue
and in semen, but the frequency of car-
riage varies considerably between
groups. Hybridization in situ revealed
HHV-8 in the prostate glandular epi-
thelium of an elderly HIV-seronegative
male11. In addition, in a cohort of Ital-
ian patients of unknown HIV status,
who had no apparent clinical disease
other than occasional varicoceles,
HHV-8 DNA was detected by polymer-
ase chain reaction (PCR) in 12% of tis-
sue specimens from the urogenital
tract, and in 44% of prostate tissues12.
In addition, 81% of ejaculates from
non-HIV-infected Italian individuals
were HHV-8 positive12. HHV-8 was de-
tected in prostate tissue of men with
KS by in situ hybridization; between
1% to 5% of cells expressed viral tran-
scripts associated with HHV-8 replica-
tion, while more than 90% expressed
gene products associated with viral la-
tency, findings suggesting that the
prostate may be a site for viral repli-
cation and subsequent shedding into
semen13.
HHV-8 DNA was detected by PCR
in semen samples of 2/15 HIV-nega-
tive and 8/15 HIV-positive men living
in Central Africa14. In contrast, HHV-8
was not detected in the semen of 4
HIV-infected American males with
KS15, and only 2 out of another cohort
of 14 HIV-infected American homo-
sexual men with KS were found to be
HHV-8 DNA positive16. Accordingly,
not all HIV-infected patients from the
US had evidence of HHV-8 in semen17.
Transmission of HHV-8 in feces was
suggested by the findings that oro-
anal contact was associated with a
higher likelihood of KS in homosexual
males7. Nevertheless, supporting evi-
dence is equivocal since HHV-8 DNA
was not detectable in feces from one
cohort of HIV-infected patients18 but
was found in 24 out 51 duodenal and
rectal biopsies from another cohort19.
Sexual transmission is unlikely to
be the only route of transmission of
HHV-8, particularly in geographic ar-
eas where HHV-8 infection is endemic,
and where prior to the AIDS era, KS
was a common tumor not subse-
quently found to be associated with
HIV infection (e.g. in Central and East
Africa)20, such as in Uganda21. A recent
study found HHV-8 infection in early
childhood in Uganda unassociated
with antibodies to hepatitis A or C vi-
rus or with the quality of water supply,
which points to a horizontal mode of
transmission different to that of devel-
oped countries22.
HHV-8 has also been found in sa-
liva of HIV-infected patients. In one
study, HHV-8 DNA was found in
unstimulated whole saliva from 25 of
76 HIV-infected individuals without
oral KS23, and another study showed
HHV-8 in the saliva of individuals
having no detectable viral sequences
in their peripheral blood mononuclear
cells24. In addition, HHV-8 DNA was
detected in the saliva of 5 of 29 (17%)
symptomatic HIV-infected patients
(only 1 had oral KS at the time of sam-
pling), but in none of 15 healthy con-
trols25 or in any of 39 HIV-negative pa-
tients26.
Parenteral transmission is another
potential route of HHV-8 infection.
The virus has been detected in CD19+
cells of a healthy blood donor27. But
in a separate study, 13 of 14 patients
were found to remain seronegative for
HHV-8 despite receiving transfused
blood cells from HHV-8 seropositive
donors28.
Data concerning a vertical route of
transmission of HHV-8 is contradictory.
In one study, all 9 children born from
HHV-8 IgG positive Haitian and
American mothers were HHV-8 seron-
egative29. However, in another study, 8
children of 19 who had HHV-8 IgG se-
ropositive mothers were also HHV-8
seropositive30. Apart from vertical
transmission, intrafamilial person-to-
person spread of the virus has also
been suggested, since the HHV-8
seroprevalence of spouses, children,
and siblings in families of KS patients
is higher than in HHV-8 non-family
controls31.
EPIDEMIOLOGY OF HHV-8
INFECTION - SEROLOGICAL
DATA
Epidemiological data based upon
the detection of IgG antibodies to
HHV-8 is conflicting, owing to meth-
odological differences and, perhaps
more importantly, geographical differ-
ences in HHV-8 infection. Using an in-
direct immunofluorescence assay (IFA)
based on nuclei of BCBL-1 cells (to
exclude the detection of cytoplasmic
antigens)32, a seroprevalence of 1%
was found in a group of HIV-negative
blood donors and 8% in HIV-negative
patients with syphilis. A study with in-
direct immunofluorescence using an
uninduced cell preparation with a high
cut-off to avoid non-specific back-
ground33 failed to detect HHV-8 anti-
bodies in a large cohort of US blood
donors. In contrast, an IFA based upon
induced cell preparations optimized
for the expression of both nuclear and
cytoplasmic antigens34 found 25% of
a cohort of healthy American adults
and 2% to 8% of children to have IgG
antibodies to HHV-8.
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An IFA that detected antibodies to
a latency-associated nuclear antigen
(LANA) found none of 195 exclusively
heterosexual men from San Francisco
to have antibodies to HHV-8, while
12.5% of men who reported mostly
homosexual activity, and 39.6% who
were exclusively homosexual were
HHV-8 positive8. More recently, using
uninduced and TPA-induced BCBL-1
cells35, IFA antibody titers to HHV-8
were found to be much higher in HIV-
infected Los Angeles patients with KS
than in those HIV-infected without KS;
furthermore, antibody positivity rate
was 8% in healthy individuals, 56% in
HIV-positive homosexual men, and
12% in age-matched HIV-negative
controls36.
Additionally, 28% of Italian blood
donors were found to be HHV-8 sero-
positive by IFA in a recent published
study37. This is similar to another study
where 23% of the control group com-
prised of healthy volunteers and pa-
tients with various dermatological dis-
eases from central and southern regions
of Italy had HHV-8 DNA in their
PBMCs38.
Using IFA, HHV-8 antibodies were
found in 16/16 French KS patients but
in only 3/83 patients with non-KS
dermatologic diseases and in 2/100
healthy controls39. Likewise, only 5/
169 (3%) of HIV negative patients
from Honduras were found to be HHV-
8 positive when using a cutoff point
of 1:4040.
Studies with enzyme-linked immu-
nosorbent assay (ELISA) utilizing
recombinant capsid-related proteins of
HHV-8 open reading frame (ORF) 65
(which has little sequence similarity to
EBV-BFRF3)41 found seroprevalence
rates of 1.7% in UK, 5% in North
American, 12% in Mediterranean blood
donors, and up to 47% in Ugandan HIV-
negative individuals. Investigations us-
ing an ELISA that utilizes 2 regions of
the ORF 26 differing substantially from
EBV-BDLF1, found 6 of 30 (20%) US
healthy blood donors to be HHV-8 se-
ropositive42. Another study, using small
viral capsid antigen (sVCA) found 3 of
28 (11%) US blood donors to be serop-
ositive for HHV-8, although none of 25
hemophiliac patients or 22 children (10
HIV-negative and 12 HIV-positive)
were HHV-8 seropositive43. In another
study, none of the 52 patients tested
who were negative for HIV and hepati-
tis B and C virus had antibodies for
HHV-844. In addition, using a latency-
associated nuclear antigen (LANA) IFA
and an ELISA with plates coated with
capsid-related protein encoded by ORF
65, 24.1% of 779 Italian blood donors
from different regions had antibodies to
at least 1 antigen45.
An ELISA for detection of the ORF
65.2 antigen showed positivity in 24/
26 (92.3%) of Swiss HIV-positive pa-
tients with KS, in 21/87 (24.1%) of
HIV-positive patients without KS, in
11/54 (20.4%) of HIV-negative homo-
sexual men, and in 9/178 (5.1%) blood
donors46. Another ELISA assay with
the whole virus lysate as the antigen
was used, and a seroprevalence of 11%
(10/91) was found in US blood donors.
In this study, the average titer of dif-
ferent groups was also measured: blood
donors had an average titer of 118,
classic KS patients had an average titer
of 14,111, and HIV-associated KS pa-
tients had 400047.
In order to standardize HHV-8 anti-
body assays, a blinded comparison was
recently performed between 5 laborato-
ries using 4 different IFAs and 3 ELISAs.
It was found that while the HHV-8 an-
tibody tests were adequate for epide-
miological investigations, the poor
specificity and sensitivity in detecting
asymptomatic HHV-8 infection re-
quired further confirmatory testing us-
ing nucleic acid detection methods48.
Most serological studies (Table 1)
suggest a global HHV-8 sero-
prevalence of 2% to 10%. Assuming a
rate of 5% HHV-8 in the US and a 1970
baseline incidence of KS in men in the
US (about 0.3 cases per 100,000 men),
the HHV-8 rate would be only 1 case
of KS for every 17,000 HHV-8 infec-
tions50.
DISEASE ASSOCIATIONS OF
HUMAN HERPESVIRUS 8
Kaposi’s sarcoma
Two small fragments of the HHV-8
genome, KS330Bam and KS631Bam, were
originally isolated from KS tissues us-
ing representational difference analy-
sis1. Since then, other research groups,
using PCR primers derived from
KS330Bam sequence, have detected
HHV-8 DNA in lesional tissues of all 3
epidemiological forms of KS: HIV-re-
lated15,51-67, endemic51,52,56,58,65,67,68-70, and
immunosuppressed related65,67,71-73.
Human herpesvirus 8 DNA can be
amplified from KS tissue in different
clinical stages of the disease74. Further-
more, semiquantitative analysis has
established that the HHV-8 DNA load
is higher in patients with multicentric
and visceral involvement compared
with those with localized disease, and
that the nodular stage also has a higher
viral load than do the patch and plaque
stages, thereby showing a correlation
between viral load and disease sever-
ity75.
The presence of HHV-8 DNA in
PBMCs of HIV-infected individuals is
predictive of the subsequent appear-
ance of KS lesions76,77. In addition, an-
tibodies to HHV-8 are associated with
having KS or being at increased risk
of developing KS78,79.
Body cavity-based lymphoma
Body cavity based-lymphoma
(BCBL) (also termed primary effusion
lymphoma (PEL)) is a rare, rapidly fa-
tal malignancy, first described in AIDS
patients.3 The disease has a distinctive
presentation, with malignant perito-
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Table 1 - HHV-8 seroprevalence in general populations.
Assay Antigen Country Seroprevalence (%) Reference
Indirect Immunofluorescence Assay Latency Associated Nuclear Antigen Us 1-8 3 2
Western Blot Lna Us 0 33
Indirect Immunofluorescence Assay Latency Associated Nuclear Antigen Us 25 3 4
Elisa Orf 65 Uk, Us, Uganda 1.7, 5, 47 41
Elisa Orf 26 Germany 11 149
Elisa Orf 26 Us 20 42
Western Blot Svca Us 11 43
Indirect Immunofluorescence Assay Orf 26/26 Us 0 44
Indirect Immunofluorescence Assay Latency Associated Nuclear Antigen Us 0 8
Indirect Immunofluorescence Assay/ Latency Associated Nuclear Antigen Us 8 3 5
Western Blot
Elisa/Indirect Immunofluorescence Latency Associated Nuclear Italy 24 4 5
Assay/Western Blot Antigen/Orf 65
Indirect Immunofluorescence Assay Latency Associated Nuclear Antigen France 2-3.6 39
Indirect Immunofluorescence Assay Latent/Lytic Us 12 79
Indirect Immunofluorescence Assay Latency Associated Nuclear Antigen France 2 94
Elisa Orf 65.2 Switzerland 5 46
Elisa Whole Virus Us 11 47
Indirect Immunofluorescence Assay Lytic/Latent Italy 28/2 37
Indirect Immunofluorescence Assay Lytic Honduras 3-11 40
neal, pericardial, or pleural effusions
in the absence of an identifiable tumor
mass or nodal involvement. Carriage
by BCBL cells of both EBV and HHV-
8 infection has been observed, but as-
sociation with HHV-8 alone has also
been reported80-83. Notably, most cases
of EBV-negative BCBL have occurred
in patients who are also HIV negative,
whereas BCBL in HIV positive pa-
tients are usually EBV-positive.
Multicentric Castleman’s disease
Multicentric Castleman’s Disease
(MCD) is an atypical lymphoproli-
ferative disorder mostly found in pa-
tients with HIV disease. HHV-8 has
been found only infrequently in MCD
of HIV negative patients4, making the
association less strong in comparison
with that of HHV-8 with KS or BCBL/
primary effusion lymphoma.
Other possible disease associations of
HHV-8
Lymphoproliferative disease
HHV-8 sequences have been de-
tected in some angioimmunoblastic
lymphadenopathies in non-HIV-in-
fected patients, in particular in a dis-
tinct, benign lymphadenopathy histo-
logically characterized by a predomi-
nantly follicular lesion with a giant
hyperplasic germinal center and in-
creased vascularity84.
HHV-8 DNA has also been de-
tected rarely in other lymphopro-
liferative disorders, including non-
Hodgkin’s lymphoma, Hodgkin’s dis-
ease, reactive lymphadenopathies85,
and cutaneous lymphoma in AIDS59.
The viral load is significantly higher
in lymphoid tissue from HIV-infected
persons as compared to HIV-seronega-
tive individuals85, although it is still
lower than in splenic tissue or PBMCs
from the same patients. This suggests
that the HHV-8 detected in these le-
sions may reflect HHV-8 carriage by
non-neoplastic B cells59. Detection of
HHV-8 in mature T-cell lymphoprolife-
rative disorders is equivocal3,86-88.
Multiple Myeloma
HHV-8 has been associated with
multiple myeloma (MM) in several US
studies. HHV-8 DNA was found in
bone marrow dendritic cells of 25% of
a cohort of patients with monoclonal
gammopathy, a condition that may
progress to MM5. HHV-8 DNA was
also found by PCR in 6 out of 7 fresh
biopsy samples, and by in situ hybridi-
zation in bone marrow dendritic cells
in 17 out of 20 patients with MM89. In
addition, 20 of 27 (81%) patients with
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MM were HHV-8 seropositive using an
ELISA assay, while only 22% of pa-
tients with other malignancies and 6%
of blood donors were found to be
HHV-8 seropositive90.
In contrast, studies in other coun-
tries have not detected HHV-8 associ-
ated with MM. Using a nested PCR
and a serological assay to detect HHV-
8 LANA and ORF 65 (lytic) protein,
only 1 out of 20 Italian patients with
MM was found to be HHV-8 seroposi-
tive91. None of 10 Swedish patients
with MM were found to be HHV-8 posi-
tive by PCR or serological assay92. Fur-
thermore, no statistically significant
differences between MM patients and
blood donors were observed in the fre-
quency of HHV-8 seropositivity using
an IFA assay76. Similar results have
also been found by others93-97. Any sig-
nificance of HHV-8 in the etiology of
MM thus remains unclear.
Other conditions
HHV-8 DNA can be detected in
normal skin of HIV-infected patients
with KS 62,64,98, and in normal skin from
patients with endemic KS12,15,65,99,100, or
in iatrogenic KS101. It is also found in
lesional tissue of patients with squa-
mous cell or basal cell carcinomas66.
The HHV-8 infection load appears to
be lower in normal skin and in cuta-
neous lesions other than KS than in
lesional KS tissue64,66.
Sequences of HHV-8 DNA have
been detected in immunosuppressed pa-
tients with glomerulonephritis54, with
pemphigus vulgaris,102 and with myco-
sis fungoides.103 HHV-8 sequences have
also been detected in angiosarco-
mas104,105 and in angiolymphoid hyper-
plasia with eosinophilia104. However,
HHV-8 DNA was not detected in immu-
nosuppression-associated dermatofibro-
mas, despite these sharing many histo-
logic similarities with HIV-related KS106.
HHV-8 has been associated with
sarcoidosis in Italian patients6, but not
in French patients107. Furthermore, a
serological assay (ELISA) detected an-
tibodies in only 3 out 15 (20%) of
Swiss patients108.
At present it is unclear if immuno-
suppression or granulomatous inflamma-
tion activate latent HHV-8 or whether the
virus is indeed an etiological agent.
Virological aspects of HHV-8
Cell lines derived from BCBL fre-
quently contain HHV-8 genomes. Their
study has thus provided significant
insights into the biological properties
of HHV-8. The BC-1 line harbors HHV-
8 but not EBV-DNA, while line BC-2
harbors both viruses3. Treatment of BC-
1 with phorbol esters rapidly induces
lytic growth of HHV-8, and progeny vi-
rus are then shed into the supporting
medium109. The induced B cells can be
observed to contain 110 nm intranu-
clear herpesvirus-like nucleocapsids
and complete cytoplasmic virions81.
The length of genome of the virus is es-
timated to be similar (e.g. 160-170 kb)
to other gammaherpesviruses. The
HHV-8 genome is, like that of EBV,
maintained in latently infected B cells
as extrachromosomal, episomal,
monomeric circles, with induction from
latency leading to the selective accu-
mulation of linear genomic forms109. In
contrast, only covalently closed, circu-
lar episomes of HHV-8 are identified in
KS tissue, while linear forms, arising
from viral replication, are additionally
found in PBCs of KS patients110. While
uninduced BCBL lines have not yet
been shown to permit propagation of
HHV-8, the virus can be cultured from
skin lesions of patients with AIDS-as-
sociated KS using the human embryo-
nal-kidney epithelioid line 293106, thus
providing evidence that the virus is
able of replicating vegetatively in vitro.
Sequencing of a 12.3-kb HHV-8
clone obtained from a genomic library
derived from BC-1 revealed homology
between HHV-8 with parts of the EBV
genome. The sequences of some ORFs
of HHV-8 are homologous to EBV-
membrane antigen p140, herpesvirus
saimiri (HVS) p160, cellular type D
cyclins, and HVS and cellular G pro-
tein-coupled receptors80. Furthermore,
transcription of these 4 ORFs can be
demonstrated in BC-12. A novel abun-
dant 1.2-kb RNA, polyadenylated nu-
clear RNA (called PAN RNA), has also
been identified from the BC-1 line; it
appears speckled in the nuclei by im-
munofluorescence and may be a early
lytic cycle viral transcript111,112.
The BC-1 cell line was used to cre-
ate a cosmid and phage genomic li-
brary, allowing full characterization of
the HHV-8 nucleotide sequence, ex-
cept for a 3 kb region at the right end
of the genome113. The BC-1 HHV-8 ge-
nome is 140.5-kb long, with a unique
coding region flanked by multiple
801-bp terminal repeat sequences. A
genomic duplication that apparently
arose in the parental tumor is present
in this cell culture-derived strain. At
least 81 ORFs and 5 internal repeat re-
gions are present in the long unique
region. In addition to viral structural
and metabolic proteins, the virus en-
codes homologues as complement-
binding proteins, 3 cytokines (2 mac-
rophage inflammatory proteins (MIP),
MIP-1a, MIP-1b, and interleukin-6, IL-
6), dihydrofolate reductase, bcl-2, in-
terferon regulatory factors, interleukin
8 receptor, neural cell adhesion mol-
ecule-like adhesin, and a D-type
cyclin113. A subsequent study in which
a 17-kb segment of HHV-8 between
ORFs 11 and 17 was sequenced con-
firmed that the viral genome contains
a single 13-kb divergent locus wherein
are 9 ORFs that are homologous with,
or related to, cellular proteins114. A
fourth potential cytokine gene, BCK,
was also identified, in addition to a vi-
ral thymidylate synthetase gene, the
T1.1 abundant lytic cycle nuclear RNA
gene, and 2 genes (1E1-A and 1E1-B)
related to the immediate-early protein
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of the gamma-2 class herpesvirus bo-
vine herpesvirus type 4114.
The herpes viral-like particles pro-
duced from BC-1 cells can further in-
fect PBMC-derived CD19+ B cells.
This suggests that HHV-8 is transmis-
sible and B-lymphotropic115.
More recently, other BCBL-derived
cell lines have been established and
characterized: BC-3, BCP-1, and CRO-
AP/3 do not contain EBV DNA, while
CRO-AP/5 and HBL-6 contains both
EBV and HHV-898,116-118. The structure
of the HHV-8 gene in these cell lines
has yet to be reported.
HHV-8 homology to other viral and
cellular proteins
Analysis of the putative translation
products of HHV-8 has revealed homol-
ogy with a number of known human
cell receptors, cell cycle enzymes, and
chemokines important in a variety of
cellular and immunological as well as
homeostatic and angiogenic mecha-
nisms. HHV-8 may thus possess a
range of mechanisms capable of caus-
ing cell changes.
HHV-8 possesses several potential
oncogenes. The open reading frame
(ORF) K1, for instance, encodes a class
I transmembrane glycoprotein with
transforming properties in rodent
fibroblasts119. The second HHV-8 po-
tential oncogene is a G protein-cou-
pled receptor (GCR), which is a puta-
tive translation product of ORF 74.
These receptors are important in cel-
lular growth and differentiation, with
some GCRs being implicated in malig-
nant transformation116. Expression of
HHV-8 GCRs stimulates proliferation
and causes transformation of rodent
fibroblasts. Hence, the HHV-8 GCR
homologue may be a mediator of KS
tumorigenesis120. The closest cellular
homologues to the putative HHV-8
GCR are the interleukin-8 (IL-8)
receptors A and B, and the closest vi-
ral homologue is the herpesvirus
samiri (HVS) ECRF3 gene, which en-
codes a functional IL-8 receptor121.
HHV-8 also contains a protein ho-
mologous with cell cycle controllers,
such as a cyclin D-type v-cyclin that
displays 53% homology to cyclin
D2122. Cyclins are required for cellular
division and are involved in the con-
trol of the G1S check point in the cell
cycle123. HHV-8 cyclin protein is re-
ported to possess kinase activity,
which enables it to phosphorylate and
thus inactivate the retinoblastoma (Rb)
tumor suppressor protein. Hence HHV-
8 has the potential to overcome cell-
cycle control, thereby increasing the
likelihood of tumor development124,125.
HHV-8 ORF 16 (vBcl-2) shares
15% to 20% amino acid identity with
the Bcl-2 family113,126,127 — a group of
genes known to prevent apoptosis.
Other ORFs of HHV-8 have been
found to encode proteins similar to
macrophage inflammatory protein
(MIP) chemokines (vMIP-1 from ORF
K6 and vMIP-2 from ORF K4),
interleukin-6 (from ORF K2), and in-
terferon regulatory factor (vIRF) (from
ORF K9)2. The HHV-8 ORF K6 protein
(vMIP-1) inhibits HIV entry via the
CCR5 chemokine receptor, suggesting
that vMIP-1 is functional in binding
CCR5 and thus contributes to interac-
tions between HHV-8 and HIV.
Potentially, HHV-8 may exert some
inhibitory action in HIV infection,
which might underlie the suggestion
that patients with AIDS and KS have a
better prognosis than patients with
AIDS but not KS128. This may not be
the case, however, since a recent epi-
demiological study found that the
presence of KS appears to accelerate
the clinical course of HIV infection re-
sulting in shorter survival times129. Fur-
thermore, vMIP-1 is expressed only by
a small subpopulation of HHV-8 in-
fected cells (productive cells), and
therefore the impact of vMIP-1 on KS
angiogenesis may be limited.130 The
virally-derived IL-6 (vIL-6) has been
found to be expressed in some HHV-8
infected cells131.
HHV-8 may thus have the means
of overcoming typical cellular strate-
gies against viral infection including
cell cycle control, apoptosis, and cell-
mediated immunity (Table 2 summa-
rizes HHV-8 genes possibly implicated
in the pathogenesis of KS).
Table 2 - HHV-8 genes implicated in tumorigenesis150.
Host cell homologue HHV-8 encoded Possible function
protein
D-Type cyclin v-Cyc Inactivation of pRB Promotes G1 to S phase
transition
IL-8 GPCR V-GPCR Cellular growth signal
Interferon regulatory v-IRF Inhibits p21 and MHC class I expression
factor
CC chemokines v-MIP-I, vMIP-II, Chemoattraction, angiogenesis
vMIP-1ß
IL-6 v-IL-6 Growth factor for KS cells
Bcl-2 family protein v-Bcl-2 Inhibition of apoptosis
FLICE inhibitory v-FLIP Inhibition of CD95L and TNF-induced
protein apoptosis
N-CAM family protein v-Ox-2 Cellular adhesion molecule
CD21/CR2 complement ORF 4 Escape from host immune response
binding protein
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Antiviral therapy
HHV-8 replication in vitro can be
inhibited by ganciclovir, foscarnet,
and cidofovir, but not acyclovir133. In
addition, lytic replication of HHV-8
can be inhibited by a low dose of
cidofovir134,135.
Highly active antiretroviral
therapy (HAART), however, is very ef-
fective in inhibiting HIV replication,
increasing CD4 + cell counts and de-
laying, lessening, or resolving AIDS-
associated opportunistic infec-
tions136,137. Preliminary data from case
reports suggest that protease inhibitors
may help induce remission of HIV-re-
lated KS125,138-143 and clearance of HHV-
8 DNA from PBMCs138,139,141,143,145.
Moreover, HAART in 2 HIV-positive
patients with BCBL resulted in HHV-
8 DNA being undetected in their pleu-
ral effusions146. In contrast, PrI treat-
ment produced no effect on the clini-
cal and virological progression of an
HIV-positive patient with MCD147.
Oral health considerations of HHV-8
infection
HHV-8 is not found in saliva of
healthy controls but is found in the
saliva of up to 33% of patients with
AIDS23 and up to 75% of HIV infected
patients with KS24. Similarly, HHV-8
DNA was found only in symptomatic
HIV-1-infected patients (5 [17%] of
29)25. More recently, 11 out of 24 sa-
liva samples (45.8%) of patients with
AIDS-KS were HHV-8 DNA positive,
but in the control group, none of the
20 saliva specimens were positive for
HHV-8 DNA38. HHV-8 has been iden-
tified in oral KS, other oral lesions (e.g.
non-specific ulcers), and in normal oral
mucosae in HIV disease148. Neverthe-
less, there are no data yet to suggest
that dental health care workers are at
notable risk of HHV-8 acquisition
through occupational routes.
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OBJETIVO: O objetivo do pre-
sente artigo foi revisar a literatura re-
cente em relação ao herpesvírus huma-
no tipo 8, com ênfase especial aos as-
pectos relacionados à etiopatogênese
do sarcoma de Kaposi.
MÉTODOS: Os autores pesquisa-
ram artigos de pesquisa original e re-
visões de literatura nos aspectos espe-
cíficos da infecção pelo herpesvírus
humano tipo 8, incluindo, virologia,
epidemiologia, transmissão, diagnósti-
co, história natural e terapia. O mate-
rial considerado relevante foi avalia-
do e revisado.
RESULTADOS: O sarcoma de
Kaposi é considerado ainda a maligni-
dade mais comumente observada em
pacientes infectados pelo HIV. Estudos
epidemiológicos, assim como os basea-
dos em técnicas de biologia molecular
indicam que um agente sexualmente
transmissível, independente do HIV,
deve estar envolvido na etiologia do
sarcoma de Kaposi, possivelmente
como resultado da ação das cell
signaling proteins superando os aspec-
tos da resposta imune. O herpesvírus
humano tipo 8 tem sido ainda sugeri-
do como agente causal na patogênese
de outras desordens, incluindo mielo-
ma múltiplo, multicentric Castleman’s
disease, body cavity-based lymphoma,
além de outras condições não-prolife-
rativas como sarcoidose e pênfigo vul-
gar, embora grande parte dos estudos
sorológicos apontem para uma soro-
prevalência em torno de 2 a 10%. O
herpesvírus humano tipo 8 parece en-
tão, ser um vírus restrito a pessoas sob
risco de desenvolver o sarcoma de
Kaposi, associado à imunossupressão. O
tratamento para o sarcoma de Kaposi é
normalmente paliativo, e inclui a apli-
cação de vimblastina intra-lesional,
crio-cirurgia, interferon-alpha e outras
formas de terapia. Mais recentemente,
os inibidores da protease, foram tam-
bém sugeridos como possíveis agentes
implicados na remissão do sarcoma de
Kaposi associado ao HIV e no desapa-
recimento do herpesvírus humano tipo
8 das células mononucleares do sangue
periférico.
CONCLUSÃO: O herpesvírus hu-
mano tipo 8 está fortemente associa-
do a todas as formas de sarcoma de
Kaposi, multicentric Castleman’s
disease e body cavity-based
lymphoma. Ainda, não existe tratamen-
to definitivo para o sarcoma de Kaposi.
DESCRITORES: Herpesvírus
humano tipo 8. KSHV. Sarcoma de
Kaposi. AIDS. HIV.
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